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Abstract
Background
Ameloblastoma is the second most common odontogenic tumor, known to be slow-growing,
persistent, and locally aggressive. Recent data suggests that ameloblastoma is best treated
with wide resection and adequate margins. Following primary excision, bony reconstruction
is often necessary for a functional and aesthetically satisfactory outcome, making early di-
agnosis paramount. Despite earlier diagnosis potentially limiting the extent of resection and
reconstruction, an understanding of the growth rate and natural history of ameloblastoma
has been notably lacking from the literature.
Method
A systematic review of the literature was conducted by reviewing relevant articles from
PubMed andWeb of Science databases. Each article’s level of evidence was formally ap-
praised according to the Centre of Evidence Based Medicine (CEBM), with data from each
utilized in a meta-analysis of growth rates for ameloblastoma.
Results
Literature regarding the natural history of ameloblastoma is limited since the tumor is imme-
diately acted upon at its initial detection, unless the patient voluntarily refuses a surgical in-
tervention. From the limited data, it is derived that the highest estimated growth rate is
associated with solid, multicystic type and the lowest rate with peripheral ameloblastomas.
After meta-analysis, the calculated mean specific grow rate is 87.84% per year.
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Conclusion
The growth rate of ameloblastoma has been demonstrated, offering prognostic and man-
agement information, particularly in cases where a delay in management is envisaged.
Introduction
Ameloblastoma is the second most common, benign, but locally aggressive odontogenic tumor
[1–3]. Most tumors arise from the mandible or maxilla, and affect between the third and fourth
decade of life. Ameloblastoma can be clinically classified into solid, multicystic or unicystic or
peripheral subtypes. The solid, multicystic type is the most common, while the unicystic type
accounts for 5–15% of the cases, affects a younger population and has 3 variants: simple, lumi-
nal and mural. Peripheral ameloblastoma is the least common and has a benign biologic behav-
ior. Ameloblastoma most often presents as a hard painless intraoral swelling or as an incidental
finding on routine dental imaging. Although histologically benign, 2–4.5% of all cases have ma-
lignant potential and metastasize, most commonly to the lung [4,5]. Hence, the goal of man-
agement entails a complete excision with linear margins and early bony reconstruction.
Adequate margins can be confirmed histologically postoperatively or radiologically with
intraoperative imaging [1,6,7]. Long-term follow-up is critical since recurrences can occur up
to 45 years after the initial resection.
Historically, ameloblastoma has been treated with curettage by community dentists or re-
sected by surgeons before a detailed histological work-up is undertaken. In these settings,
under-treatment and the persistent biologic behavior of ameloblastoma has resulted in high re-
currence rates and morbidity. Given the potential for significant destruction of local anatomy,
locoregional recurrences and metastatic potential, a clear understanding of the natural history
of ameloblastoma is warranted. Such information can give a guide as to the urgency of manage-
ment, guide treatment approaches and offer prognostic information. However, this under-
standing is notably absent from the literature.
In the current study, we have conducted a systematic review of the literature and a meta-
analysis of 16 reports, from which the documented tumor dimensions and the duration of
symptoms have been used to derive at a quantitative growth rate of ameloblastoma. Such un-
derstanding of the growth and natural history of ameloblastoma will be useful when offering
treatment options at varying growth phases.
Methods
Search Strategy and Selection Criteria
The current study comprises of a systematic review of the literature and a meta-analysis, aim-
ing to establish the growth and natural history of ameloblastoma. We performed a comprehen-
sive search of the databases including PubMed and Web of Science for eligible studies
published between Jan 1, 1950, and May 27, 2014. Search terms were a combination of “amelo-
blastoma” with “growth”, “growth rate”, “natural history”, “untreated”, “declined surgery”,
“giant”, or “extreme”. Additional references identified through the reference lists of selected
references and bibliographic linkage were included in the review. A PRISMA (Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses) flowchart for literature attrition is
included (Fig. 1) [8]. Only papers published or translated in English were reviewed.
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Fig 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart for
literature attrition in systematic review [8].
doi:10.1371/journal.pone.0117241.g001
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The following inclusion criteria were applied for the meta-analysis: human case reports/
series of benign ameloblastoma before the initial surgical intervention and where all three di-
mensions of the tumor (i.e. length x width x height) and the duration of symptoms were re-
ported. We excluded studies reporting the growth of ameloblastic carcinoma, malignant
ameloblastoma, and recurrent ameloblastoma, in vitro cellular growth or molecular studies, re-
ports where only one or two dimensions of the tumor volume were reported.
Data Extraction
We developed a data abstraction sheet, to record necessary information to establish the level of
evidence, study quality, and available outcome and risk factor details. Bias risk was evaluated
and the level of evidence was assessed formally according to CEBM (Centre for evidence Based
Medicine) evidence level. The CEBM (http://www.cebm.net) attributes standardized levels of
evidence, from level 1a (systematic review of randomized control trials) to level 5 (expert opin-
ion), to any research paper. Each of the included studies was thus critically appraised based on
their study design and content. For meta-analysis, we recorded patient age, sex, tumor volume,
mode of volume measurement, duration of symptoms, and histological subtype.
Data Synthesis and Analysis
Two authors (MPC and WMR) independently screened records and assessed each retrieved
full-text articles for inclusion. Disagreements were resolved by a blinded third reviewer
(DJHS).
Studies inconsistently documented the tumor volume from either the surgical specimen, the
plain radiograph, or from clinical examination. We considered the direct measurement from a
surgical specimen the most accurate, then radiographs, and clinical examination in descending
order. Hence, where the tumor volume was mentioned multiple times in a report, we would se-
lect the most accurate volume.
We extracted tumor volume dimensions from each study and the duration of symptoms in
order to derive the specific growth rate (SGR; growth % per year) of each case. SGR was calcu-
lated using a formula previously described to quantify the tumor response to anti-cancer treat-
ment [9]. Mehrara et al [9] mentions a logarithm of the ratio of post-treatment tumor volume
(V2) to the pre-treatment tumor volume (V1) divided by the duration of treatment (T2-T1)
(Equation 1).
SGR ¼ lnðV2=V1Þ
T2  T1
1
For appropriate calculation in our study, V1 was considered “1” and T1 as “0”.
Statistical Analysis
Statistical software, STATA (Version 13; StataCorp; College Station, TX, USA) was used for
analysis. Initially, we treated SGR as a continuous variable and utilized Kruskal-Wallis equali-
ty-of-populations rank test. We calculated the statistical association between SGR and gender
or three age groups (0–20, 21–40, 41 years and older). Then, we divided SGR into two groups:
less than 100% per year and equal to or more than 100%. Using Pearson’s chi-squared test, we
compared SGR against different histological subtypes (plexiform and follicular versus the rest),
the three age groups, and gender. In all analyses, a p value lower than 0.05 was used as the level
of statistical significance.
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Role of the Funding Source
There was no funding source for this study. All authors had full access to the data included in
the study and had final responsibility for the decision to submit for publication.
Results
Literature Review
Systematic review of the literature identified 2 formal papers that discuss the natural history
and growth rate of ameloblastoma. In a retrospective review of 100 cases of ameloblastoma,
Odukoya et al report a superior average growth rate in the solid, multicystic subtype, compared
to the peripheral subtype (0.81 vs 0.17 cm3/month respectively) [10]. In a similar study, the
same authors have retrospectively analyzed the maximal tumor diameter from 330 biopsy spec-
imens and found that the solid, multicystic type grows more aggressively than desmoplastic
ameloblastomas (0.71 vs 0.36 cm/month respectively) [11].
Through rigorous assessment (Fig. 1), we also identified 16 published reports where the
tumor volume and the duration of symptoms before receiving any treatment were known.
They were utilized for the subsequent meta-analysis and to derive the SGR [12–27].
Natural History and Growth Rate of Ameloblastoma
Throughout the literature, cases have been reported where patients with ameloblastoma did
not receive immediate primary surgical interventions for various reasons—economic, fear of
surgery, ignorance—and presented with a large solid, multicystic ameloblastoma [12–27].
Using the inclusion and exclusion criteria mentioned previously, we have identified and ana-
lyzed 16 published cases to calculate SGR of benign ameloblastoma (Table 1). The average age
is 41 year-old (range: 10–62) and females are more frequently reported (2.67:1). There are six
plexiform, two follicular, and one acanthomatous histological subtypes, and two are unknown.
Mean duration of symptoms is 9.04 years (range: 0.17–23).
We have only perused reports where all three dimensions of the tumor volume are known
in order to attain the most accurate estimate of the volume for calculating SGR. We excluded
studies of ameloblastoma carcinoma or malignant ameloblastoma since they display signifi-
cantly different biological behaviors [4]. Ameloblastic carcinoma histologically exhibits malig-
nant features. Even though histologically appear benign, malignant ameloblastoma tend to
metastasize to distant sites in contrast to benign ameloblastomas. Furthermore, we have limited
our search to the clinical cases and omitted studies of in vitro growth rate or expression of pro-
liferative cell markers. They do not adequately account for the complex multi-factorial in vivo
environmental elements contributing to the tumor growth.
Using the formula devised by Mehrara et al [28] for our meta-analysis, the mean SGR was
initially calculated as 298% per year (range: 37.37–3356.83). Interestingly, once the outlier
(3356.83% [14]) is removed, the mean SGR decreases significantly to a more reasonable
87.84% (range: 37.37–169.98). Pramulio et al [14] acknowledge that the patient’s history may
have been unreliable and the duration of symptom may have been much longer.
Factors Associated with More Rapid Growth
The calculated growth rates as above are based on averages from the reported series. This is
clearly not a reflection of the tumor biology nor the intrinsic growth of ameloblastoma and its
subtypes, but of the average calculated rates. We have analyzed our findings to identify factors
that would be potentially associated with a higher SGR. Interestingly, none of the factors—
gender, age groups, and histological subtypes—have shown statistical significance with SGR
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(Table 2). The most statistical significance is found where histological subtypes divided into
two subgroups—plexiform and follicular versus the rest—are correlated to SGR also divided
into two subgroups—less than 100% versus equal to or more than 100% (p = 0.14). This dis-
crepancy is most likely due to the small sample size (n = 16). Unfortunately given the fact that
most cases of ameloblastoma are almost universally treated immediately upon detection, it
may be difficult to perform a study like this in a large scale.
Notwithstanding, in the literature, there are other factors that have established a clear corre-
lation with more rapid growth and a poorer outcome. These include maxillary ameloblastoma
when compared to the mandible [29], the solid, multicystic histological subtype, unicystic sub-
type invading the fibrous wall [30], older age (as young age is associated with unicystic amelo-
blastoma, and hence, better outcome) [31], malignant ameloblastoma, and suboptimal
treatment (e.g. curettage, enucleation).
Table 1. Characteristics of large ameloblastoma cases reported in the literature.
Age (year) Sex Volume (cm) Weight
(gram)
Mode of
measurement
Duration of
Symptoms
(years)
SGR
(%/year)
Histological
Type
Level of Evidence
and Study Quality
Hunasgi[23] 39 F 12.0 x 10.0 x 9.0 1200 Surgical 10 69.85 Granular cell 4
Catherine[24] 48 F 30.0 x 18.0 x 10.0 N/A Radiographic 23 37.37 Follicular &
plexiform
4
Mijiti[25] 40 M 25.0 x 20.0 x 15.0 N/A Radiographic 15 59.48 Desmoplastic 4
Ota[22] 32 F 27.2 x 20.3 x 15.1 1600 Surgical 10 90.28 Acanthomatous 4
Chauhan[21] 42 F 15.0 x 14.0 x 10.0 N/A Surgical 4.5 169.98 Plexiform 4
Acharya[26] 35 F 15.0 x 12.0 x 10.0 1350 Surgical 10 74.95 Plexiform 4
Hata[20] 53 M 14.0 x 11.0 x 10.0 N/A Clinical 11 66.72 Follicular 4
Mukhopadhyay
[27]
32 M 25.0 x 15.0 x 10.0 N/A Surgical 7 117.56 N/A 4
Hughes[19] 53 F 15.2 x 11.4 x 12.0 1280 Surgical 6 127.32 Plexiform 4
Dunn[18] 62 F 17.0 x 15.0 x 13.0 1282 Radiographic 6 135.10 Plexiform 4
Gordy[17] 19 F 8.0 x 6.0 x 6.0 N/A Surgical 5 113.19 Follicular 4
Ueyama[16] 73 M 10.0 x 9.0 x 7.5 435 Surgical 10 65.13 Plexiform 4
Nakasato[15] 39 F 11.0 x 10.0 x 6.0 386 Clinical 6 108.18 Plexiform 4
Pramulio[14] 10 M 9.0 x 6.0 x 5.0 N/A Clinical 0.17 3356.83 Unknown 4
Osaki[13] 30 F 14.0 x 13.0 x 12.0 936 Surgical 7 109.84 Plexiform 4
Rambo[12] 41 F 21.0 x 15.0 x 15.0 N/A Surgical 14 60.43 Unknown 4
Abbreviations: N/A: not applicable; SGR: specific growth rate.
doi:10.1371/journal.pone.0117241.t001
Table 2. Summary of statistical analysis of patient factors against the specific growth rate of the tumor.
P values Gender Age group Plexiform and follicular vs other histological subtypes
SGR as a continuous variable 0.24 0.68 N/A
SGR in 2 groups 0.31 0.25 0.14
Abbreviations: SGR: specific growth rate; vs: versus; N/A: not applicable.
doi:10.1371/journal.pone.0117241.t002
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Discussion
Background
An understanding of the growth of ameloblastoma mandates a “control group” of ameloblas-
toma from which its natural history can be derived. For decades, ameloblastoma has been treat-
ed primarily surgically, either conservatively or radically, at the time of its first presentation
without confirmatory histological diagnosis. This has meant that few studies offer any informa-
tion about the untreated growth of these tumors. Furthermore, due to its rare nature, most re-
ports have been limited to small-scale case studies. By combining data from all eligible
published reports, we have derived at a quantitative growth rate of benign ameloblastoma. De-
spite the relatively small sample size (n = 16), the information will be useful for planning man-
agement, especially in the early stages of tumor growth.
While most authors would simply describe ameloblastoma as a slow growing tumor, a
group in Nigeria has quantified its growth rate [10,11]. Odukoya et al [10] report a level 4 ret-
rospective analysis of 100 ameloblastoma cases treated in a single center. They have calculated
estimated monthly growth rate of the tumors in order to predict the “biologic aggression” of in-
dividual subtypes by dividing the average tumor volume at presentation to the duration of
symptoms. Consistent with the literature, the solid, multicystic ameloblastoma has the fastest
growth rate and the peripheral subtype the slowest (0.81 versus 0.17 cm3/month, respectively).
Limitations of this study include the assumption that ameloblastoma follows linear growth.
Furthermore, the mechanism of tumor volume measurement (e.g. clinically versus radiologi-
cally) and the reasoning behind the selection of 100 cases are not clarified. Moreover, the au-
thors acknowledge their reliance on the patients to provide accurate history. Interestingly, the
same authors [11] would later use the largest tumor diameter to compare the estimated growth
rate of desmoplastic ameloblastoma and the conventional solid, multicystic type in another
level 4 retrospective study of 330 biopsy specimens. The limitations are similar to the previous
study but, in addition, the latter analyses only a small sample size of desmoplastic specimens
(n = 14). They conclude that desmoplastic ameloblastoma may be less biologically aggressive
compared to the solid, multicystic type (0.36 versus 0.71 cm/month, respectively) due to the
desmoplasia acting as a tumor-limiting barrier.
For meta-analysis, we have used the formula mentioned by Mehrara et al [9]. In contrast to
the more traditional tumor doubling time, SGR (Equation 1) more accurately reflects the natu-
ral exponential growth of the tumour [9]. Odukoya et al [10] and Effiom et al [11] simply di-
vide the tumor volume or diameter by the symptom duration to arrive at an estimated monthly
growth rate, which falsely assumes a linear growth pattern. In fact, evidences show that amelo-
blastoma initially exhibits slow growth, but later its growth accelerates [13,14,32]. Pramulio
et al [14] reports a 10 year-old boy with a 2 month history of right jaw swelling that grows sub-
stantially in the few weeks prior to the presentation. Osaki et al [13] mentions a 30 year-old fe-
male with a 7 year history of left mandibular swelling that accelerates to the lower jaw 3 years
before presentation. Rajaonarison Ny Ony et al [32] describes a case of maxillary ameloblas-
toma in a 23 year-old female growing slowly for 15 years before exhibiting accelerated growth
in the 5 weeks preceding to the presentation.
Symptomatically, patients with ameloblastoma initially present with painless intraoral
swelling. Early complications include generalized edema and anemia secondary to selective
hypoproteinemia from transudation through the semipermeable cyst wall and bleeding from
the ulcerations respectively. These are resistant to aggressive medical treatment. Later compli-
cations are associated with obstruction leading to small mouth opening, such as difficulty with
mastication, deglutition, phonation and airway obstruction, as well as the loss of dentition on
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the ipsilateral side. It is worth noting that all of the metabolic derangements improved dramati-
cally after radical tumor resection.
Management of Benign Ameloblastoma
Despite its benign histology, ameloblastoma is associated with significant morbidities and is fatal
if suboptimally treated [33,34]. Complete surgical removal of tumor and restoration of function
and appearance are the main goal of therapy [6,35]. Surgical intervention is popularly classified
into conservative resection with or without adjunctive therapy, and radical resection. Tumor ex-
cision is ideally followed by reconstruction with a bone graft or flap, distraction osteogenesis and
dental prostheses [36]. Reconstruction is easier if done earlier due to absence of scarring or con-
tracture, and it can be beneficial psychologically. Radiotherapy and chemotherapy have no role
in ameloblastoma management. Radiation used alone is associated with 100% failure rate and se-
rious complications, such as osteomyelitis leading to death and sarcoma development [37].
Conservative Resection
Conservative surgical approach, such as curettage and enucleation, is frequently used for the
treatment of unicystic ameloblastoma, except in the mural variant where the epithelium in-
vades the cyst wall [3,38,39]. Although technically straightforward, curettage or enucleation
can be associated with high recurrence rates (30–90%) when used against more aggressive
solid, multicystic ameloblastomas [2,40–43]. Moreover, curettage or enucleation may not be
able to remove the tumor tissue from within the cancellous bone beyond the macroscopic ap-
pearance and radiographic boundary. Hence, conservative resection has widely only been ad-
vocated in solid, multicystic ameloblastomas for patients of less than 10 years of age or smaller
tumors [44]. Interestingly, evidence has also been offered that even for unicystic ameloblasto-
mas, curettage or enucleation may still be associated recurrence rates (35–60%) higher than
radical excision [35,45–48]. Furthermore, the luminal and intraluminal variants of unicystic
ameloblastoma are difficult to differentiate from the mural type preoperatively, leading to the
risk of “under-treatment” [49].
In order to improve its efficacy, curettage or enucleation can be paired with cryotherapy
[50], electrocautery [51] or application of cauterizing agents like Carnoy’s solution [52]. De-
spite encouraging early results [53–55], the combination of curettage and cryotherapy has a re-
currence rate (31%) higher than radical resection and is also associated with pathological
fracture (11%) and wound dehiscence (30%) [50]. Hence, this is not appropriate where soft tis-
sue extension and cortical thinning or perforations are present. The results are similarly unre-
markable with electrocautery and Carnoy’s solution.
Radical Resection
A radical approach—either marginal or segmental resection with adequate margin—ensures
maximal removal of solid, multicystic ameloblastoma, minimizing the recurrence rate (0–10%)
and the risk of metastasis [41,56–60]. Some literature suggests that ameloblastoma can extend
into cancellous bone histologically at a mean of 4.5 mm (range: 2.3–8 mm) beyond the radio-
graphic boundary [61] and currently, the literature recommends the use of 1–1.5 cm resection
margin [48]. Satisfactory margins can be achieved by the application of new specialized imag-
ing techniques, such as flat panel volumetric CT (fpvCT) [1], which can provide accurate ana-
tomical details for intraoperative margin assessment.
In maxillary ameloblastoma, early radical resection is especially beneficial. Although less
common and histologically similar to mandibular ameloblastoma, maxillary ameloblastoma
acts clinically more aggressive. Maxilla lacks the thick cortical bone found in mandible that can
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slow down the tumor growth. Furthermore, maxillary ameloblastoma can potentially invade
the central nervous system [29,40,62] and the rate of surgical cure decreases significantly once
the tumor has extended beyond the confines of the maxillary bone [63]. In contrast, peripheral
ameloblastomas are relatively innocuous with no bone involvement and can be sufficiently
managed with a local excision and a long-term follow-up of the surgical site [64].
Marginal resection for solid, multicystic ameloblastoma is advantageous since it preserves
the inferior margin of the mandible and prevents the necessity of a complex bone reconstruc-
tion [65]. However, where radical marginal resection may result in jaw instability and an in-
creased risk of pathological fractures, segmental resection with bony reconstruction is the
preferred option [6]. Furthermore, the unexcised inferior margin of mandible may present a
source of tumor recurrence [65]. Jaw reconstruction techniques with a bone graft or a flap are
now well described in the literature and are associated with relatively low morbidity [66].
Bony Reconstruction
An understanding of the natural history of ameloblastoma can potentially limit the extent of
resection and reconstruction. Conservative resection through enucleation or marginal resec-
tion can facilitate a limited reconstruction, with either no reconstruction at all, or bone graft re-
construction. In this setting, either autologous or alloplastic options are available, which can
each fill the resection defect and provide form and/or strength to the remaining facial skeleton.
Where a segmental alveolar defect exists, in either mandible or maxilla, a bone graft can be
used for smaller defects, particularly those less than 5 cm in length. A bone graft in this setting
can be derived from the iliac crest (most commonly) [67,68], fibula [69], scapula [70], rib [71]
or the radius [72]. A bone graft can be broadly classified as non-vascularized or vascularized. A
non-vascularized bone graft heals by ‘creeping substitution’, in which there is a combination of
osteoblast migration and bony scaffold graft take, while the framework maintains structural in-
tegrity during this process. Compared to alloplastic or vascularized options, bone grafts can
provide a better bulk of bone for the placement of dental implants, a superior contour, under-
goes remodeling upon placement and is associated with shorter hospital stays and decreased
number of subsequent operations. Hence, a non-vascularized bone graft is indicated where the
bony defect is shorter and an adequate amount of soft tissue is available. Handschel et al [73]
recommends non-vascularized iliac crest graft for mandibular defects up to 5–6 cm in length.
Since the average length of defect experienced by the author was 4.9 cm, the graft is suitable for
most cases. Increased graft length is associated with an increased graft failure rate [74]. Pogrel
et al [75] reports 75% failure rate for grafts longer than 12 cm and recommends extreme cau-
tion when using grafts longer than 9 cm. Additional advantages of a bone graft include being
able to prepare and insert one in the same operation with the primary resection [76]. In addi-
tion, it provides a superior function in regard to mastication and deglutition [77]. Successful
graft uptake is assessed by the maintenance of bone continuity, complete consolidation with
the absence of infection examined clinically in the operating theatre or on imaging [78]. Poten-
tial complications are infection, fracture and plate exposure [73]. In addition, a variable degree
of bony resorption is associated with bone grafts [56].
For a larger bony defect or where inadequate soft tissue is available, a free flap (vascularized
bone graft) is suggested instead. The ability to vascularize a bone based on its intrinsic vasculature
has meant that large segments, large enough to reconstruct the entire alveolus, can be transferred
safely in a single stage. As for bone grafts, the iliac crest, fibula, scapula, rib and radius have all
been described in this setting. These flaps can be transferred as pedicled or free flaps, and can also
be transferred as bone only, or composite flaps. While useful in complex situations, these flaps
mandate lengthy operative times, increased length of hospital stays and patient morbidity.
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Length of Follow-Up
Given the biologic behavior of ameloblastomas, a long-term follow-up is mandatory. More
than 50% of recurrences occur within 5 years of the primary surgical intervention [3]. Howev-
er, sporadic reports of recurrences at 20, 30 and 45 years have been reported in the literature
[79–82]. Of note, higher recurrence rate is reported in granular and follicular histological sub-
types [3]. Inadequately short follow-up may give physicians a false indication of cure and a po-
tential to miss metastatic ameloblastoma [3].
Conclusion
Current meta-analysis has produced a mean SGR of 87.84% growth per year for benign amelo-
blastoma, after removing outliers, which offers prognostic and management information, par-
ticularly in cases where a delay in management is envisaged. The greatest growth rate may be
associated with plexiform and follicular histological subtypes, but this did not reach statistical
significance. Early intervention can limit subsequent growth and facilitate more conservative
reconstructive options.
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